>KG – Further comment on embeda the morphine/naltrexone combo. The two leading branded morphines are avinza (king) and Kadian (al pharma). I wonder if the ftc will force kg to divest one or both.<
Before the merger, ALO’s plan was to cease promoting Kadian upon FDA approval of Embeda. (Embeda was originally called Kadian NT.)
I presume KG would happily accept a modest sum from any company who wanted the marketing rights to Kadian; the question is whether anyone will want them.
Market Data 
Markets 
AI
